MED

MEDIFAST INC MED

NYSESmall CapConsumer Staples

13F Pro quality score

Rank #2,797 of 2,925

Why it scores 17Consumer Staples peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$72.05M

Quarter to Sep 30

Net income

$-17.51M

Quarter to Sep 30

Free cash flow

$2.87M

Quarter to Sep 30

Operating margin

-26.9%

Quarter to Sep 30

Top Institutional Holders

as of Q2 2026
$87.67M total
RENAISSANCE TECHNOLOGIES LLC
$8.26M+0.6%
Steamboat Capital Partners, LLC
$7.50M-0.1%
TWO SIGMA INVESTMENTS, LP
$5.11M+42.4%
VANGUARD CAPITAL MANAGEMENT LLC
$4.74M+0.5%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$4.21M-37.1%
BlackRock, Inc.
$3.92M-60.9%
DIMENSIONAL FUND ADVISORS LP
$3.86M+0.5%
AMERICAN CENTURY COMPANIES INC
$3.38M+42.2%
MORGAN STANLEY
$3.10M-10.1%
GOLDMAN SACHS GROUP INC
$2.58M+58.7%
MARSHALL WACE, LLP
$2.56MNew
AQR CAPITAL MANAGEMENT LLC
$2.51M+62.4%
Peapod Lane Capital LLC
$2.36M+1.6%
Lido Advisors, LLC
$2.34M+20.4%
Trexquant Investment LP
$2.26M+18.1%
JANE STREET GROUP, LLC
$1.75M+30.4%
COMMONS CAPITAL, LLC
$1.59M+294.5%
Quinn Opportunity Partners LLC
$1.35M0.0%
GEODE CAPITAL MANAGEMENT, LLC
$1.29M-52.2%
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$1.24M-25.5%
RBF Capital, LLC
$1.16MNew
JPMORGAN CHASE & CO
$989.9K+6.1%
D. E. Shaw & Co., Inc.
$979.8K-42.5%
BANK OF AMERICA CORP /DE/
$924.3K-1.9%
Quantinno Capital Management LP
$880.6K+47.8%
See all 114 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q3 2026
EDGAR

Net Income

Q3 2026
EDGAR

EPS (Diluted)

Q3 2026
EDGAR

Operating Margin

Q3 2026
EDGAR

ROIC

Q3 2026
EDGAR

Free Cash Flow

Q3 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/MED

Earnings Per Share

13fpro.ai/company/MED

Loading ratio trend…

MED key financials by period

Reported revenue, net income and operating margin by fiscal year, from MEDIFAST INC's annual filings on SEC EDGAR.

MEDIFAST INC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$385.8M$-18.7M-3.7%
FY 2024$602.5M$2.1M0.5%
FY 2023$1.1B$99.4M11.8%
FY 2022$1.6B$143.6M11.6%
FY 2021$1.5B$164.0M14.2%
FY 2020$934.8M$102.9M14.3%
Source: MED filings on SEC EDGAR →

Companies similar to MED

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

MED insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About MEDIFAST INC (MED): stock profile, AI score and financials

MEDIFAST INC (MED) stock profile, AI quality score, and SEC EDGAR financial data, a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores MED at 16.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,797 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.9) and institutional flow (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 39.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), MEDIFAST INC reports quarterly revenue of $72.0M, net income of $-17.5M, an operating margin of -26.9%. Top institutional holders of MED by reported 13-F value include RENAISSANCE TECHNOLOGIES, Steamboat Capital Partners, TWO SIGMA INVESTMENTS, based on the most recent SEC filings. MED trades on the NYSE exchange and files with the SEC under CIK 910329. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MED daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MEDIFAST INC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 910329 →